Mode
Text Size
Log in / Sign up

Protocol outlines AI/ML approaches to identify TB transmission drivers and treatment failure factors in Uganda.

Protocol outlines AI/ML approaches to identify TB transmission drivers and treatment failure factors…
Photo by Jonathan Kemper / Unsplash
Key Takeaway
Note this protocol outlines planned AI/ML research for TB transmission factors in Uganda; no results available.

This document is a study protocol detailing a planned research initiative focused on Tuberculosis and HIV/TB coinfection. The proposed study will be conducted in Kampala city, Uganda, targeting TB patients and their contacts. The intervention involves the application of health data science approaches, specifically AI/ML algorithms, aimed at identifying factors driving TB transmission and reasons for anti-TB treatment failure. No comparator or specific medication interventions are defined in this protocol.

The protocol outlines several secondary outcomes intended for evaluation. These include identifying patients at baseline who are unlikely to convert their sputum or culture results by months 2 and 5. Additionally, the study aims to identify household contacts of TB cases who are at risk of developing TB disease and to identify contacts who may resist TB infection despite repeated exposure to M. tuberculosis. The follow-up period for these assessments is set at months 2 and 5.

Critical details regarding the study design remain undefined in this protocol. The sample size is not reported, and the primary outcome is not reported. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, are not reported as the study has not yet commenced. Funding sources and potential conflicts of interest are not reported. Consequently, the certainty of any future findings cannot be assessed at this stage, and no causal conclusions can be drawn from this planning document.

Practice relevance is not reported for this protocol. Clinicians should note that this document represents a research plan rather than completed evidence. Until the study is executed and results are published, the proposed use of AI/ML algorithms in this setting remains a hypothesis rather than a validated strategy for clinical management.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Tuberculosis (TB) is prevalent in Uganda and overlaps with a high rate of HIV/TB coinfection. While nearly all hospital-based TB cases in Kampala, the capital of Uganda, show clear TB symptoms, 30% or more of undiagnosed TB cases found through active screening are asymptomatic. Additionally, the host risk factors for TB in Kampala cannot be distinguished from environmental risk factors. These TB-specific challenges are just part of the complexity, especially in areas with high HIV/AIDS burden. Data science techniques, especially Artificial Intelligence (AI) and Machine Learning (ML) algorithms, could help untangle this complexity by identifying factors related to the host, pathogen, and environment, which are difficult to explain or predict with traditional/conventional methods. In this project, we will use health data science approaches (AI/ML) to identify factors driving TB transmission within households and reasons for anti-TB treatment failure. We will utilize the computational resources at Makerere University and available demographic, clinical, and laboratory data from TB patients and their contacts to develop AI and ML algorithms. These will aim to: (1) identify patients at baseline (month 0) unlikely to convert their sputum or culture results by months 2 and 5, thus at risk of failing TB treatment; (2) identify household contacts of TB cases who are at risk of developing TB disease, as well as contacts who may resist TB infection despite repeated exposure to M. tuberculosis. Achieving these objectives will provide evidence that data science methods are effective for early detection of potential TB cases and high-risk patients, thereby helping to reduce TB transmission in the community. The study protocol received approval from the School of Biomedical Sciences IRB, protocol number SBS-2023-495.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.